JP2009528390A - 薬用ラトランキュリン製剤 - Google Patents

薬用ラトランキュリン製剤 Download PDF

Info

Publication number
JP2009528390A
JP2009528390A JP2008557515A JP2008557515A JP2009528390A JP 2009528390 A JP2009528390 A JP 2009528390A JP 2008557515 A JP2008557515 A JP 2008557515A JP 2008557515 A JP2008557515 A JP 2008557515A JP 2009528390 A JP2009528390 A JP 2009528390A
Authority
JP
Japan
Prior art keywords
latrunculin
formulation
aqueous
buffer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008557515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528390A5 (https=
Inventor
クリシュナムーシー，ラメシュ
エー． トレビーノ，レオ
エム． エバンス，リチャード
Original Assignee
インスパイアー ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスパイアー ファーマシューティカルズ，インコーポレイティド filed Critical インスパイアー ファーマシューティカルズ，インコーポレイティド
Publication of JP2009528390A publication Critical patent/JP2009528390A/ja
Publication of JP2009528390A5 publication Critical patent/JP2009528390A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008557515A 2006-03-02 2007-03-02 薬用ラトランキュリン製剤 Withdrawn JP2009528390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77927306P 2006-03-02 2006-03-02
US11/680,893 US7785624B2 (en) 2006-03-02 2007-03-01 Pharmaceutical latrunculin formulations
PCT/US2007/063171 WO2007103782A2 (en) 2006-03-02 2007-03-02 Pharmaceutical latrunculin formulations

Publications (2)

Publication Number Publication Date
JP2009528390A true JP2009528390A (ja) 2009-08-06
JP2009528390A5 JP2009528390A5 (https=) 2010-04-15

Family

ID=38475717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557515A Withdrawn JP2009528390A (ja) 2006-03-02 2007-03-02 薬用ラトランキュリン製剤

Country Status (10)

Country Link
US (2) US7785624B2 (https=)
EP (1) EP1993563A4 (https=)
JP (1) JP2009528390A (https=)
KR (1) KR20080098636A (https=)
AU (1) AU2007223378A1 (https=)
BR (1) BRPI0708483A2 (https=)
CA (1) CA2644198A1 (https=)
MX (1) MX2008011112A (https=)
RU (1) RU2434633C2 (https=)
WO (1) WO2007103782A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523292A (ja) * 2016-08-02 2019-08-22 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014240A2 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of California Novel bioactive small molecules derived from sea sponges
EP3397651B1 (en) 2015-12-29 2020-05-06 Galderma S.A. Carbohydrate crosslinker
US20220047719A1 (en) * 2020-08-17 2022-02-17 Northwestern University Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (minp)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3677421B2 (ja) * 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
CN101160315A (zh) * 2005-03-25 2008-04-09 印斯拜尔药品股份有限公司 细胞骨架的活性化合物，组合物及用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523292A (ja) * 2016-08-02 2019-08-22 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物
JP2022089867A (ja) * 2016-08-02 2022-06-16 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物
JP7386080B2 (ja) 2016-08-02 2023-11-24 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物
JP7542028B2 (ja) 2016-08-02 2024-08-29 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物

Also Published As

Publication number Publication date
WO2007103782A3 (en) 2008-03-20
EP1993563A4 (en) 2009-05-20
US7785624B2 (en) 2010-08-31
RU2434633C2 (ru) 2011-11-27
US20100305175A1 (en) 2010-12-02
KR20080098636A (ko) 2008-11-11
EP1993563A2 (en) 2008-11-26
RU2008139113A (ru) 2010-04-10
CA2644198A1 (en) 2007-09-13
WO2007103782A2 (en) 2007-09-13
MX2008011112A (es) 2008-09-08
AU2007223378A1 (en) 2007-09-13
US20070225343A1 (en) 2007-09-27
BRPI0708483A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
AU2022204216B2 (en) Compositions and methods of using nintedanib for improving glaucoma surgery success
CN111867560B (zh) 包含噻吗洛尔的药物组合物
WO1993024121A1 (fr) Medicament pour le glaucome
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
JP7080268B2 (ja) 一酸化窒素放出プロスタミドを含有する眼科用組成物
US7785624B2 (en) Pharmaceutical latrunculin formulations
CA2306371C (en) Use of flunarizine for the topical treatment of glaucoma
TWI868659B (zh) 無防腐劑的眼科藥物乳劑及其應用
CN101394856A (zh) 红海海绵素药物制剂
RU2781022C2 (ru) Офтальмологические композиции, содержащие простамид, высвобождающий окись азота
JP2741285B2 (ja) 緑内障治療剤
Abelson et al. 27 Tear Substitutes
HK40000005B (zh) 使用尼达尼布改善青光眼手术成功情况的组合物和方法
HK40000005A (en) Compositions and methods of using nintedanib for improving glaucoma surgery success
HK1228731A1 (en) Ophthalmic formulations of squalamine
HK1185566A (zh) 角鲨胺的眼用制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100301

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120119